The Intellectual Property Appellate Board (IPAB) in Chennai has concluded the hearing of Bayer’s appeal against the Indian Patent Office’s compulsory licencing case. The German drug giant had appealed against the Patent
When Cipla, the second largest pharma company in India, announced that it is slashing prices of three anti-cancer drugs used to treat brain, lung and kidney cancer it sent shockwaves in the pharma world.
Cipla’s move will
Bayer AG isn’t going to take the compulsory licensing verdict lying down. In March, the Indian Patent Office, in a game-changing ruling allowed Natco, an Indian firm to replicate Bayer’s blockbuster cancer drug Nexavar. This
Cipla, one of the biggest Indian pharmaceutical companies today announced that they have reduced the price of the generic drug, Soranib from Rs 28,000 to Rs 6,840, a decrease of almost 80%. This move seems to be influenced by the
On Friday Swiss drugmaker Roche Holding announced plans to launch two cut-price blockbuster cancer drugs for the Indian market soon. Roche, the world’s biggest maker of cancer drugs, said it would offer “significantly”